Gujarat Kidney And Super Speciality Limited has informed the Exchange about change in Management
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The company reported strong financial performance for FY2026. Standalone profit after tax grew 8.7% to Rs. 990.14 Lacs (from Rs. 910.90 Lacs), while consolidated profit more than doubled to Rs. 1,681.18 Lacs (from Rs. 949.94 Lacs). Consolidated revenue from operations doubled to Rs. 8,201.34 Lacs. Notably, the CEO appointment agenda was explicitly deferred by the Board, contrary to the headline suggesting a management change. The company raised Rs. 25,079.56 Lacs through equity issuance (net of Rs. 3,330.12 Lacs in share issue expenses). New appointments include Siddharth Atulbhai Shah as Internal Auditor for FY2026-27 and SPANJ & Associates as Secretarial Auditor for 5 years. A postal ballot is being conducted for shareholder approval on variation in objects of IPO.
Despite strong financial growth, the deferred CEO appointment and large equity raise with IPO object variation suggests potential corporate restructuring ahead. No immediate management change occurred, contrary to the exchange notification headline.